NEW YORK, NY / ACCESSWIRE / April 9, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/inovio-pharmaceuticals-inc-loss-submission-form?prid=5983&wire=1
Lead Plaintiff Deadline: May 12, 2020
Class Period: February 14, 2020 to March 9, 2020
According to a filed complaint, throughout the class period, defendants made misleading statements about the company's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses.
VMware, Inc. (NYSE:VMW)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/vmware-inc-loss-submission-form?prid=5983&wire=1
Lead Plaintiff Deadline: June 1, 2020
Class Period: March 30, 2019 to February 27, 2020
Allegations against VMW include that: (i) VMware's reporting with respect to its backlog of unfilled orders was not in compliance with all relevant accounting and disclosure requirements; (ii) the foregoing subjected the Company to a foreseeable risk of heightened regulatory scrutiny and/or investigation; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Gossamer Bio, Inc. (NASDAQ:GOSS)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/gossamer-bio-inc-loss-submission-form?prid=5983&wire=1
Lead Plaintiff Deadline: June 2, 2020
Class Period: common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with its February 8, 2019 initial public offering.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose: (1) the reasons for Gossamer's GB001 trial failures; (2) the purported clinical validation of Novartis' oral DP2 antagonist; and (3) that, as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong